Development of an inactivated vaccine candidate for SARS-CoV-2

Science
Qiang GaoChuan Qin

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.

Associated Clinical Trials

References

Jun 1, 1996·Vaccine·A D MurdinS Plotkin
Jan 22, 2002·Perception & Psychophysics·J Miller, R Ulrich
Jun 5, 2003·Lancet·John M NichollsJ S Malik Peiris
Nov 6, 2014·Molecular Biology and Evolution·Lam-Tung NguyenBui Quang Minh
Aug 21, 2019·Frontiers in Microbiology·Chean Yeah YongWen Siang Tan
Jan 30, 2020·Viruses·Lisa E Gralinski, Vineet D Menachery
Feb 28, 2020·Asian Pacific Journal of Allergy and Immunology·Eakachai PrompetcharaTanapat Palaga
Mar 4, 2020·Nature Microbiology·UNKNOWN Coronaviridae Study Group of the International Committee on Taxonomy of Viruses
Apr 1, 2020·The New England Journal of Medicine·Nicole LurieJane Halton
Apr 9, 2020·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Paola Stefanelli On Behalf Of Iss Covid-Study Group
Apr 23, 2020·Animal Models and Experimental Medicine·Pin YuChuan Qin

❮ Previous
Next ❯

Citations

Jun 24, 2020·Microbial Biotechnology·Harald Brüssow
May 10, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tulika SinghSallie R Permar
Jul 15, 2020·Critical Reviews in Clinical Laboratory Sciences·Bingliang Fang, Qing H Meng
Aug 28, 2020·Frontiers in Immunology·Vibhuti Kumar ShahSamit Chattopadhyay
Jul 23, 2020·Science·Yongfei CaiBing Chen
Aug 12, 2020·Drug Development Research·Cristiano Colalto
Aug 13, 2020·Nature Reviews. Immunology·Stylianos BournazosJeffrey V Ravetch
Jul 31, 2020·Nature·Neeltje van DoremalenVincent J Munster
Sep 4, 2020·Signal Transduction and Targeted Therapy·Xiangyu ChenLilin Ye
Sep 8, 2020·Environmental Microbiology·Harald Brüssow
Aug 28, 2020·Vaccines·Mohammed A Rohaim, Muhammad Munir
Sep 29, 2020·Frontiers in Immunology·Clarisa B Palatnik-de-Sousa
Jun 12, 2020·Virologica Sinica·Changhua YiJunwei Li
Jul 1, 2020·Turkish Journal of Biology = Türk Biyoloji Dergisi·Murat TopuzoĞullariSerap Derman
May 22, 2020·Science·Jingyou YuDan H Barouch
Sep 9, 2020·Emerging Microbes & Infections·Tingting LiNingshao Xia
Sep 12, 2020·Nature Reviews. Immunology·Faith OsierMelinda Suchard
Sep 5, 2020·Advanced Healthcare Materials·Eduardo Ruiz-HitzkyPilar Aranda
Aug 25, 2020·Journal of Medical Virology·Ji-Ming Chen
Aug 21, 2020·Signal Transduction and Targeted Therapy·Shuaiyao LuXiaozhong Peng
Sep 17, 2020·Human Vaccines & Immunotherapeutics·Idris Nasir AbdullahiAbdurrahman El-Fulaty Ahmad
Jun 11, 2020·Viruses·Alexander S JurekaChristopher F Basler
Jul 15, 2020·Journal of Virology·Gustaf AhlénUNKNOWN representing the OPENCORONA consortia
Aug 8, 2020·AAPS PharmSciTech·Jieliang WangRobert O Williams
Jul 30, 2020·The Journal of Pharmacology and Experimental Therapeutics·Zeenat A ShyrWei Zheng
Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Sep 24, 2020·Nature·Florian Krammer
Sep 25, 2020·Current Opinion in HIV and AIDS·Xin LiJasper Fuk-Woo Chan
Sep 11, 2020·Nature Microbiology·Wen Shi LeeBrandon J DeKosky
Jul 30, 2020·The New England Journal of Medicine·Kizzmekia S CorbettBarney S Graham
Sep 4, 2020·Human Vaccines & Immunotherapeutics·Patrick O'Connell, Yasser A Aldhamen
Jul 14, 2020·Nature·Ann M ArvinHerbert W Virgin
Sep 29, 2020·Frontiers in Immunology·Inmaculada Sanclemente-AlamanUlises Gómez-Pinedo
Sep 20, 2020·International Journal of Molecular Sciences·Arun Samidurai, Anindita Das
Jun 5, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiaoli WangQuanyi Wang
Aug 15, 2020·Frontiers in Immunology·Lea Skak Filtenborg FrederiksenAneesh Thakur

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage
enzyme-linked immunosorbent assays
ELISA

Related Concepts

Related Feeds

Antibody-Dependent Enhancement

Antibody-dependent enhancement of viral infection is the entry of virus into host cells mediated by antiviral antibodies interacting with Fc or complement receptors. This has been most extensively observed with the dengue virus. Find the latest research on antibody-dependent enhancement here.